” said Dr. Silviu Itescu, Chief Executive of Mesoblast. “With Ryoncil approval by FDA, Mesoblast has demonstrated the ability to bring the first
Remestemcel-L被FDA授予快速通道资格,这一过程促进了对严重疾病的开发和快速审查,这些疾病完全满足了医疗需求。可能的治疗方法也被授予优先审查指定。 参考来源:Mesoblast Resubmits Biologics License Application (BLA) with United States Food & Drug Administration (FDA) for Approval of Ryoncil® in Children wit...